Security
Mineralys Therapeutics, Inc. Common Stock · MLYS
MLYSNASDAQCommon stockCurrentCIK 1933414Updated Oct 3, 2026
MLYS price & chart
Loading TradingView…
NASDAQ:MLYS on TradingView ↗About the company
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.
In the news
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 661,806,000Source | 205,903,000Source | 251,636,000Source | 114,442,000Source |
| Property, Plant and Equipment, NetUSD | 38,000Source | 53,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 172,921,000Source | 114,091,000Source | 49,304,000Source | 87,701,000Source |
| Assets, CurrentUSD | 661,386,000Source | 205,351,000Source | 249,103,000Source | 112,811,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,751,000Source | 7,164,000Source | 12,536,000Source | 2,701,000Source |
| Other Assets, NoncurrentUSD | 382,000Source | 499,000Source | 51,000Source | 1,631,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 8,000Source | 5,000Source | 4,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 1,103,854,000Source | 493,770,000Source | 365,858,000Source | 540,000Source |
| Retained Earnings (Accumulated Deficit)USD | -457,169,000Source | -302,518,000Source | -124,708,000Source | -52,810,000Source |
| Stockholders' Equity Attributable to ParentUSD | 646,693,000Source | 191,257,000Source | 241,154,000Source | -52,269,000Source |
| Liabilities and EquityUSD | 661,806,000Source | 205,903,000Source | 251,636,000Source | 114,442,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 15,113,000Source | 14,646,000Source | 10,482,000Source | 8,067,000Source |
| Accounts Payable, CurrentUSD | 2,017,000Source | 479,000Source | 601,000Source | 1,907,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 13,096,000Source | 14,167,000Source | 9,881,000Source | 6,160,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 59,000Source | 43,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 19,324,000Source | 11,336,000Source | 5,060,000Source | 455,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -142,416,000Source | -166,314,000Source | -81,173,000Source | -29,221,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -389,753,000Source | 114,959,000Source | -160,472,000Source | -21,759,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 590,999,000Source | 116,142,000Source | 203,248,000Source | 128,019,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 58,830,000Source | 64,787,000Source | -38,397,000Source | 77,039,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 172,921,000Source | 114,091,000Source | 49,304,000Source | 87,701,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 19,324,000Source | 11,336,000Source | 5,060,000Source | 455,000Source |
| General and Administrative ExpenseUSD | 38,595,000Source | 23,822,000Source | 14,296,000Source | 5,229,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -154,651,000Source | -177,810,000Source | -71,898,000Source | -29,799,000Source |
| Nonoperating Income (Expense)USD | 15,953,000Source | 14,593,000Source | 12,759,000Source | 1,680,000Source |
| Operating ExpensesUSD | 170,604,000Source | 192,403,000Source | 84,657,000Source | 31,479,000Source |
| Other Nonoperating Income (Expense)USD | 0Source | 5,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 12,786,000Source | 297,000Source | 194,000Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -170,604,000Source | -192,403,000Source | -84,657,000Source | -31,479,000Source |
| Other Nonoperating Income (Expense)USD | 0Source | 5,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -154,651,000Source | -177,810,000Source | -71,898,000Source | -29,799,000Source |
| Earnings Per Share, BasicUSD per share | -2.29Source | -3.66Source | -1.99Source | -5.77Source |
| Earnings Per Share, DilutedUSD per share | -2.29Source | -3.66Source | -1.99Source | -5.77Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 67,656,355Source | 48,539,795Source | 36,188,254Source | 5,167,296Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 67,656,355Source | 48,539,795Source | 36,188,254Source | 5,167,296Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 38,595,000Source | 23,822,000Source | 14,296,000Source | 5,229,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 15,953,000Source | 14,588,000Source | 12,756,000Source | 1,676,000Source |
| Nonoperating Income (Expense)USD | 15,953,000Source | 14,593,000Source | 12,759,000Source | 1,680,000Source |
| Operating ExpensesUSD | 170,604,000Source | 192,403,000Source | 84,657,000Source | 31,479,000Source |
| Research and Development ExpenseUSD | 132,009,000Source | 168,581,000Source | 70,361,000Source | 26,250,000Source |
Filing attachments
mlys2026q28kex991.htm · 8-K · 2026-08-11
EX-99.1 3 mlys2026q28kex991.htm EX-99.1 Document Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval - - Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as Chief Medical Officer to lead the Company’s medical and late-stage clinical activities - - Strengthened balance sheet and enhanced …
Read attachment ↗mlys2026q18kex991.htm · 8-K · 2026-05-06
EX-99.1 2 mlys2026q18kex991.htm EX-99.1 Document Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, PA - May 6, 2026 - Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related como…
Read attachment ↗